Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
What is Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory (PBLLR)?
Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory (PBLLR) is an aggressive and life-threatening type of blood cancer that occurs in young adults and children. It can affect any age, gender, or race. PBLLR is a type of lymphoblastic leukemia that has not responded to treatment and is considered to be refractory to treatment. PBLLR is a rare form of leukemia that occurs when a rapidly growing type of white blood cell called lymphoblasts produce in excess of normal. The excessive production of these cells crowds out the other healthy cells in the blood, resulting in anemia, infections, and other symptoms.
What Are the Symptoms of PBLLR?
- Fatigue
- Anemia
- Frequent infections
- Night sweats
- Weight loss
- Enlarged liver or spleen
How is PBLLR Diagnosed?
A diagnosis of PBLLR is made through a combination of physical exams, blood tests, imaging scans, and biopsies. Blood tests are used to determine the number and types of cells in your blood. Imaging scans can also be used to detect any masses or enlargement in the organs. A biopsy is conducted to confirm the diagnosis by confirming the presence of abnormal lymphoblasts.
Treatment
Treatment for PBLLR is based on the patient’s age, the stage of their disease, and their overall health. To stop the further progression of the disease, chemotherapy is generally used. Radiation therapy may also be used to kill any remaining cancer cells. Additional treatments may include stem cell transplantation, targeted therapy, and immune therapy. Surgery is not used to treat PBLLR.
